Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage trial are ...
The holiday season kicks into high gear with Thanksgiving weekend, and there are plenty of special events in New Orleans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback